Delivery Order SPE2DB25D3008-SPE2DB25FRBVX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.48, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a $5,426.92 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract contains no set-aside designation and will be performed at...
- The Defense Logistics Agency awarded a $9,274.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials with an ultimate completion date of October 10, 2025. This is a non-set-aside competitive award issued as a child contract under AmerisourceBergen's larger indefinite delivery vehicle. The place of performance is the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order represents a discrete fulfillment under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,654.33 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 20, 2025, with a completion date of September 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The order will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $6,055.26 to AmerisourceBergen Drug Corp for ProQuad vials on August 5, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order valued at $1,687.48 to AmerisourceBergen Drug Corp for ProQuad vials with an ultimate completion date of October 3, 2025. This firm fixed-price delivery order, issued on September 12, 2025, represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $6,115.45 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with performance in Conshohocken, Pennsylvania and a completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The prime vendor contract serves as a comprehensive global...
- The Defense Logistics Agency awarded a $52,272.03 delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. ProQuad is a combination vaccine protecting against measles, mumps, rubella, and varicella, making...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $2,740.40 with an ultimate completion date of August 19, 2025. This firm fixed price, competitively awarded delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,480.98 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 21, 2025. This competitive award, issued on July 31, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor for federal medical...
- SPE2DB25D3008Indefinite Delivery Contract
- SPE2DB25D3008-SPE2DB25FRBVXDelivery Order
The Defense Logistics Agency awarded a $5,480.98 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of May 12, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor serving federal medical procurement needs. ProQuad is a combination vaccine indicated for prevention of measles, mumps, rubella, and varicella. This delivery order reflects AmerisourceBergen's role as a critical vaccine and pharmaceutical supplier supporting military and federal healthcare systems. The contract demonstrates the company's continued participation in DLA's pharmaceutical supply chain, which encompasses a comprehensive range of vaccines, specialty medications, generic drugs, and medical supplies across multiple therapeutic domains. AmerisourceBergen's SPE2DX vehicle is positioned as a global pharmaceutical support vehicle enabling supply to military healthcare programs worldwide, with DLA planning future iterations of its Pharmaceutical Prime Vendor Global Program potentially involving multiple regional contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.5k | 4/21/25 |